纳米材料在肿瘤放疗增敏中的进展
Progress in the Application of Nanomaterials for Radio Sensitization in Tumor Radiotherapy
DOI: 10.12677/acm.2025.151261, PDF,    国家科技经费支持
作者: 吴淞名*, 石恒煜*, 黄强强, 梁华庚#：华中科技大学同济医学院附属协和医院泌尿外科，湖北 武汉
关键词: 纳米材料；放疗增敏；肿瘤治疗；金属纳米颗粒；碳基纳米材料；靶向治疗；Nanomaterials； Radiosensitization； Tumor Therapy； Metallic Nanoparticles； Carbon-Based Nanomaterials； Targeted Therapy
摘要: 肿瘤是威胁人类生命健康的主要疾病之一。尽管放射治疗(放疗)在许多恶性肿瘤的治疗中取得了显著成效，但由于正常组织的损伤和肿瘤细胞的放射抗性，放疗效果常常受到限制。传统的放疗方法存在靶向性差、治疗效果有限、对正常组织的辐射损伤等问题，这使得其治疗效果面临诸多挑战。为了克服这些缺陷并提高治疗效果，放疗增敏策略应运而生。近年来，纳米材料作为一种新型的放疗增敏剂，凭借其优异的物理化学特性和靶向性，成为了放疗增敏研究中的重要方向。纳米材料能够通过多种机制增强肿瘤细胞对辐射的敏感性，从而提高放疗的治疗效果，并减少对正常组织的损伤。本综述回顾了纳米材料在放疗增敏中的作用机制和研究进展，并总结了不同类型的纳米材料的优势与挑战，探讨了其在肿瘤放疗中的应用前景。
Abstract: Radiotherapy (RT) is a common treatment for various malignant tumors; however, its effectiveness is often limited by normal tissue damage and the radiation resistance of tumor cells. In recent years, the application of nanomaterials in tumor radiotherapy has become a research hotspot, particularly in radiosensitization. Nanomaterials can enhance the sensitivity of tumor cells to radiation through various mechanisms, thereby improving the therapeutic effects of RT. This review summarizes the mechanisms and recent advances in the use of different types of nanomaterials (such as metallic nanoparticles, carbon-based nanomaterials, and nano-drug carriers) in radiosensitization. Through strategies such as surface modification, drug loading, and targeted delivery, nanomaterials can enable precise targeted therapy, enhancing the efficacy of radiotherapy.
文章引用：吴淞名, 石恒煜, 黄强强, 梁华庚. 纳米材料在肿瘤放疗增敏中的进展[J]. 临床医学进展, 2025, 15(1): 1963-1971. https://doi.org/10.12677/acm.2025.151261

参考文献

[1] Loap, P., Loirat, D., Berger, F., Rodrigues, M., Bazire, L., Pierga, J., et al. (2022) Concurrent Olaparib and Radiotherapy in Patients with Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncology, 8, 1802-1808. [Google Scholar] [CrossRef] [PubMed]
[2] Tutt, A.N.J., Garber, J.E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., et al. (2021) Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 384, 2394-2405. [Google Scholar] [CrossRef] [PubMed]
[3] Robson, M., Im, S., Senkus, E., Xu, B., Domchek, S.M., Masuda, N., et al. (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 377, 523-533. [Google Scholar] [CrossRef] [PubMed]
[4] Fuertes, M.A., Alonso, C. and Pérez, J.M. (2003) Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chemical Reviews, 103, 645-662. [Google Scholar] [CrossRef] [PubMed]
[5] Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P. and Vymetalkova, V. (2020) 5-Fluorouracil and Other Fluoropyrimidines in Colorectal Cancer: Past, Present and Future. Pharmacology & Therapeutics, 206, Article ID: 107447. [Google Scholar] [CrossRef] [PubMed]
[6] Er, O., Tuncel, A., Ocakoglu, K., Ince, M., Kolatan, E.H., Yilmaz, O., et al. (2020) Radiolabeling, in Vitro Cell Uptake, and in Vivo Photodynamic Therapy Potential of Targeted Mesoporous Silica Nanoparticles Containing Zinc Phthalocyanine. Molecular Pharmaceutics, 17, 2648-2659. [Google Scholar] [CrossRef] [PubMed]
[7] Farhood, B., Mortezaee, K., Goradel, N.H., Khanlarkhani, N., Salehi, E., Nashtaei, M.S., et al. (2018) Curcumin as an Anti‐Inflammatory Agent: Implications to Radiotherapy and Chemotherapy. Journal of Cellular Physiology, 234, 5728-5740. [Google Scholar] [CrossRef] [PubMed]
[8] Shah, Z., Gohar, U.F., Jamshed, I., Mushtaq, A., Mukhtar, H., Zia-UI-Haq, M., et al. (2021) Podophyllotoxin: History, Recent Advances and Future Prospects. Biomolecules, 11, Article 603. [Google Scholar] [CrossRef] [PubMed]
[9] Schaue, D. and McBride, W.H. (2015) Opportunities and Challenges of Radiotherapy for Treating Cancer. Nature Reviews Clinical Oncology, 12, 527-540. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, S., Cheng, M., Wang, S., Jiang, W., Yang, F., Shen, X., et al. (2024) A Self‐Catalytic No/O2 Gas‐Releasing Nanozyme for Radiotherapy Sensitization through Vascular Normalization and Hypoxia Relief. Advanced Materials, 36, Article ID: 2403921. [Google Scholar] [CrossRef] [PubMed]
[11] Hainfeld, J.F., Slatkin, D.N. and Smilowitz, H.M. (2004) The Use of Gold Nanoparticles to Enhance Radiotherapy in Mice. Physics in Medicine and Biology, 49, N309-N315. [Google Scholar] [CrossRef] [PubMed]
[12] Le Guével, X., Henry, M., Motto-Ros, V., Longo, E., Montañez, M.I., Pelascini, F., et al. (2018) Elemental and Optical Imaging Evaluation of Zwitterionic Gold Nanoclusters in Glioblastoma Mouse Models. Nanoscale, 10, 18657-18664. [Google Scholar] [CrossRef] [PubMed]
[13] Carigga Gutierrez, N.M., Clainche, T.L., Bulin, A., Leo, S., Kadri, M., Abdelhamid, A.G.A., et al. (2024) Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement. Advanced Materials, 36, Article ID: 2404605. [Google Scholar] [CrossRef] [PubMed]
[14] Huang, Y., Lü, X., Chen, R. and Chen, Y. (2020) Comparative Study of the Effects of Gold and Silver Nanoparticles on the Metabolism of Human Dermal Fibroblasts. Regenerative Biomaterials, 7, 221-232. [Google Scholar] [CrossRef] [PubMed]
[15] Morais, M., Machado, V., Figueiredo, P., Dias, F., Craveiro, R., Lencart, J., et al. (2023) Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiotherapy Sensitivity on Clear Cell Renal Cell Carcinoma. Antioxidants, 12, Article 2051. [Google Scholar] [CrossRef] [PubMed]
[16] Tamborini, M., Locatelli, E., Rasile, M., Monaco, I., Rodighiero, S., Corradini, I., et al. (2016) A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation to Reach Infiltrating Tumor Niches in Glioblastoma. ACS Nano, 10, 2509-2520. [Google Scholar] [CrossRef] [PubMed]
[17] Xu, P., Ma, J., Zhou, Y., Gu, Y., Cheng, X., Wang, Y., et al. (2023) Radiotherapy-Triggered in Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response via Antigen-Capturing Nanoadjuvants. ACS Nano, 18, 1022-1040. [Google Scholar] [CrossRef] [PubMed]
[18] Liao, Y., Wang, D., Gu, C., Wang, X., Zhu, S., Zheng, Z., et al. (2024) A Cuproptosis Nanocapsule for Cancer Radiotherapy. Nature Nanotechnology, 19, 1892-1902. [Google Scholar] [CrossRef] [PubMed]
[19] You, Y., Chang, Y., Pan, S., Bu, Q., Ling, J., He, W., et al. (2024) Cleavage of Homonuclear Chalcogen‐Chalcogen Bonds in a Hybrid Platform in Response to X‐ray Radiation Potentiates Tumor Radiochemotherapy. Angewandte Chemie, 137, e202412922. [Google Scholar] [CrossRef] 
[20] Luo, K., Guo, W., Yu, Y., Xu, S., Zhou, M., Xiang, K., et al. (2020) Reduction-Sensitive Platinum (IV)-Prodrug Nano-Sensitizer with an Ultra-High Drug Loading for Efficient Chemo-Radiotherapy of PT-Resistant Cervical Cancer in Vivo. Journal of Controlled Release, 326, 25-37. [Google Scholar] [CrossRef] [PubMed]
[21] Bonvalot, S., Rutkowski, P.L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M., et al. (2019) NBTXR3, a First-In-Class Radioenhancer Hafnium Oxide Nanoparticle, Plus Radiotherapy versus Radiotherapy Alone in Patients with Locally Advanced Soft-Tissue Sarcoma (Act.In.Sarc): A Multicentre, Phase 2–3, Randomised, Controlled Trial. The Lancet Oncology, 20, 1148-1159. [Google Scholar] [CrossRef] [PubMed]
[22] Li, R., Zhao, W., Han, Z., Feng, N., Wu, T., Xiong, H., et al. (2024) Self‐cascade Nanozyme Reactor as a Cuproptosis Inducer Synergistic Inhibition of Cellular Respiration Boosting Radioimmunotherapy. Small, 20, Article ID: 2306263. [Google Scholar] [CrossRef] [PubMed]
[23] Cline, B.L., Jiang, W., Lee, C., Cao, Z., Yang, X., Zhan, S., et al. (2021) Potassium Iodide Nanoparticles Enhance Radiotherapy against Breast Cancer by Exploiting the Sodium-Iodide Symporter. ACS Nano, 15, 17401-17411. [Google Scholar] [CrossRef] [PubMed]
[24] Yin, M., Yuan, Y., Huang, Y., Liu, X., Meng, F., Luo, L., et al. (2024) Carbon-Iodine Polydiacetylene Nanofibers for Image-Guided Radiotherapy and Tumor-Microenvironment-Enhanced Radiosensitization. ACS Nano, 18, 8325-8336. [Google Scholar] [CrossRef] [PubMed]
[25] Zhu, S., Gu, C., Gao, L., Du, S., Feng, D. and Gu, Z. (2024) Lipiodol Emulsion as a Dual Chemoradiation-Sensitizer for Pancreatic Cancer Treatment. Journal of Controlled Release, 374, 242-253. [Google Scholar] [CrossRef] [PubMed]
[26] Barth, R.F., Mi, P. and Yang, W. (2018) Boron Delivery Agents for Neutron Capture Therapy of Cancer. Cancer Communications, 38, 1-15. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, L., Liu, Y.H., Chou, F. and Jiang, S. (2018) Clinical Trials for Treating Recurrent Head and Neck Cancer with Boron Neutron Capture Therapy Using the Tsing‐Hua Open Pool Reactor. Cancer Communications, 38, 1-7. [Google Scholar] [CrossRef] [PubMed]
[28] Zhou, Y., Cheng, K., Liu, B., Cao, Y., Fan, J., Liu, Z., et al. (2024) Recent Progress of Nano-Drugs in Neutron Capture Therapy. Theranostics, 14, 3193-3212. [Google Scholar] [CrossRef] [PubMed]
[29] Li, Y., Cho, M.H., Lee, S.S., Lee, D., Cheong, H. and Choi, Y. (2020) Hydroxychloroquine-Loaded Hollow Mesoporous Silica Nanoparticles for Enhanced Autophagy Inhibition and Radiation Therapy. Journal of Controlled Release, 325, 100-110. [Google Scholar] [CrossRef] [PubMed]
[30] Ferreira, C.A., Goel, S., Ehlerding, E.B., Rosenkrans, Z.T., Jiang, D., Sun, T., et al. (2021) Ultrasmall Porous Silica Nanoparticles with Enhanced Pharmacokinetics for Cancer Theranostics. Nano Letters, 21, 4692-4699. [Google Scholar] [CrossRef] [PubMed]
[31] Wu, Y., Qin, J., Gu, Y., Zhao, G., Xu, P., Lin, S., et al. (2024) Radioresponsive Delivery of Toll-Like Receptor 7/8 Agonist for Tumor Radioimmunotherapy Enabled by Core-Cross-Linked Diselenide Nanoparticles. ACS Nano, 18, 2800-2814. [Google Scholar] [CrossRef] [PubMed]
[32] Chen, Q., Chen, J., Yang, Z., Xu, J., Xu, L., Liang, C., et al. (2019) Nanoparticle‐enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy. Advanced Materials, 31, Article ID: 1802228. [Google Scholar] [CrossRef] [PubMed]
[33] Shen, W., Pei, P., Zhang, C., Li, J., Han, X., Liu, T., et al. (2023) A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-immunotherapy. ACS Nano, 17, 23998-24011. [Google Scholar] [CrossRef] [PubMed]
[34] Hsu, C., Lin, J., Wei, M., Chen, L., Liang, H.T. and Lin, F. (2025) Local Delivery of Carboplatin-Loaded Hydrogel and Calcium Carbonate Enables Two-Stage Drug Release for Limited-Dose Radiation to Eliminate Mouse Malignant Glioma. Biomaterials, 312, Article ID: 122746. [Google Scholar] [CrossRef] [PubMed]
[35] Ma, X., Jiang, X., Wang, Z., Fan, Y., Li, J., Chow, C., et al. (2024) Cationic Metal‐Organic Layer Delivers Sirnas to Overcome Radioresistance and Potentiate Cancer Radiotherapy. Angewandte Chemie, 2024, e202419409. [Google Scholar] [CrossRef] 
[36] Lu, D., Li, W., Tan, J., Li, Y., Mao, W., Zheng, Y., et al. (2024) STING Agonist Delivered by Neutrophil Membrane-Coated Gold Nanoparticles Exerts Synergistic Tumor Inhibition with Radiotherapy. ACS Applied Materials & Interfaces, 16, 53474-53488. [Google Scholar] [CrossRef] [PubMed]
[37] Wang, Z., Ren, X., Li, Y., Qiu, L., Wang, D., Liu, A., et al. (2024) Reactive Oxygen Species Amplifier for Apoptosis-Ferroptosis Mediated High-Efficiency Radiosensitization of Tumors. ACS Nano, 18, 10288-10301. [Google Scholar] [CrossRef] [PubMed]
[38] Fu, S., Li, Y., Shen, L., Chen, Y., Lu, J., Ran, Y., et al. (2024) Cu2WS4‐PEG Nanozyme as Multifunctional Sensitizers for Enhancing Immuno‐radiotherapy by Inducing Ferroptosis. Small, 20, Article ID: 2309537. [Google Scholar] [CrossRef] [PubMed]
[39] Feng, Q., Qi, F., Fang, W., Hu, P. and Shi, J. (2024) Ferroptosis to Pyroptosis Regulation by Iron-Based Nanocatalysts for Enhanced Tumor Immunotherapy. Journal of the American Chemical Society, 146, 32403-32414. [Google Scholar] [CrossRef] [PubMed]
[40] Xu, Q., Zhang, H., Liu, H., Han, Y., Qiu, W. and Li, Z. (2022) Inhibiting Autophagy Flux and DNA Repair of Tumor Cells to Boost Radiotherapy of Orthotopic Glioblastoma. Biomaterials, 280, Article ID: 121287. [Google Scholar] [CrossRef] [PubMed]

为你推荐